Cevipabulin fumarate is primarily investigated for its potential in cancer therapy. It functions as a microtubule inhibitor, disrupting the normal assembly and disassembly of microtubules, which are crucial for cell division. This mechanism makes it a promising candidate for targeting rapidly dividing cancer cells. Research has focused on its efficacy in treating various types of cancers, including solid tumors, by halting tumor growth and inducing apoptosis. Additionally, its fumarate salt form enhances solubility and bioavailability, improving its therapeutic potential. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in combination with other anticancer agents.